Abatay Sel, Figen

Profile URL
https://hdl.handle.net/20.500.14627/1269
Name Variants
Sel, Figen Abatay Abatay-Sel, Figen Abatay Sel, Figen Sel, F. Abatay
Job Title
Dr. Öğr. Üyesi
Email Address
figen.sel@fbu.edu.tr
Main Affiliation
Patoloji Laboratuvar Teknikleri Programı
Status
Current Staff
Website
ORCID ID
0000-0002-1155-1284
Scopus Author ID
57211020552
Turkish CoHE Profile ID
Google Scholar ID
XQ5azmgAAAAJ
WoS Researcher ID
HPG-1322-2023

Sustainable Development Goals

SDG data could not be loaded because of an error. Please refresh the page or try again later.
No records found in other affiliations.
Bibliometrics data could not be loaded because of an error. Please refresh the page or try again later.

Filters

20252

Settings

Author of Publication: search.filters.isAuthorOfPublication.98c5f3d0-753d-4b79-9169-31fe7e2faa43

Scholarly Output Search Results

Now showing 1 - 2 of 2
  • Article
    Comparison of HLA-G Levels for Cord Blood Derived-MSC and Wharton's Jelly Derived-MSC
    (Walter de Gruyter GmbH, 2025) Abatay Sel, Figen; Erol Bozkurt, Ayse; Karatas, Sule; Suleymanoglu, Mediha; Yasa, Beril; Yasa, Cenk; Savran Oguz, Fatma; Oǧuz, Fatma Savran; Sel, Figen Abatay; Bozkurt, Ayşe Erol
    Objectives: A special group of stem cells with multipotent and immunomodulatory properties are mesenchymal stem cells (MSCs). Many modulatory factors are thought to mediate immunomodulatory properties of MSCs. One of these modulatory factors is thought to be HLA-G, one of human leukocyte antigens (HLA). This study aimed to compare HLA-G levels in both stimulated and unstimulated of peripheral blood mononuclear cell (PBMC) cultures with "cord blood-MSC" (CB-MSC) and "Wharton's jelly-MSC" (WJ-MSC) at different rates and different incubation periods. Methods: WJ-MSCs were obtained by explant method, and CB-MSCs using Ficoll-paque. They were characterized by flow cytometry. MSCs and PBMCs were directly co-cultured for 24 and 72 h at 1:5 and 1:10, respectively. After incubations, the media were collected and HLA-G levels were measured by ELISA. Results: In the unstimulated group, the highest HLA-G level was found in the PBMC:WJ-MSC-72-1:5 group, while the lowest HLA-G level was found in the PBMC:CB-MSC-72-1:5. When 24-1:5 and 72-1:5 groups were examined, the HLA-G level decreased significantly in CB-MSC groups compared to WJ-MSC, while it increased significantly in the 24-1:10 and 72-1:10 groups (p<0.05). In stimulated groups, the highest HLA-G level was observed in the PBMC:CB-MSC-24-1:5. Conclusions: Our study aimed to evaluate the immunomodulatory effect of MSCs via HLA-G molecule. HLA-G levels changed with different incubation times of two different MSC sources. In this study, we suggest that MSCs as a cell therapy, in particular for immune system-related disease, may be a preliminary in vitro approach to evaluate the immunomodulatory effect via HLA-G.
  • Book Part
    Cell-Based Therapy for Cancer in Regenerative Medicine
    (CRC Press, 2025) Sel, Figen Abatay; Oǧuz, Fatma Savran
    Regenerative medicine focuses on developing and applying new cell-based therapies to heal tissues and organs and restore function lost due to aging, disease, tissue damage, or cancer. Cancer is a complex disease. It can occur with dysfunction in multiple systems, including DNA repair and apoptotic and immune functions. One form of regenerative medicine is cancer immunotherapy. In cancer immunotherapy, the immune system is activated, replaced, engineered, or regenerated to fight cancer. Stem cells are the most widely used for cancer immunotherapy. Stem cells have a natural capacity for self-healing via asymmetric division. Mesenchymal stem cells (MSCs) are a specific group of stem cells that have the potential to be used most often in regenerative medicine. In addition to MSCs, induced pluripotent stem cells (iPSCs) and hematopoietic stem cells (HSCs) are used in regenerative medicine for cancer treatment. This chapter will discuss using different types of stem cells in other cancers and the pros and cons of using stem cell-based therapies. © 2025 Elsevier B.V., All rights reserved.